<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-MedLine.d44">
    <sentence id="DDI-MedLine.d44.s0" text="Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease.&#xd;&#xa;">
        <entity id="DDI-MedLine.d44.s0.e0" charOffset="11-20"
            type="drug" text="etofibrate"/>
    </sentence>
    <sentence id="DDI-MedLine.d44.s1" text="Slow chylomicron intravascular catabolism has been associated with coronary artery disease and screening for drugs that can speed-up this process can be important. "/>
    <sentence id="DDI-MedLine.d44.s2" text="In this study, the effects of etofibrate upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day etofibrate or placebo for 1-month. ">
        <entity id="DDI-MedLine.d44.s2.e0" charOffset="30-39"
            type="drug" text="etofibrate"/>
        <entity id="DDI-MedLine.d44.s2.e1" charOffset="401-410"
            type="drug" text="etofibrate"/>
        <pair id="DDI-MedLine.d44.s2.p0" e1="DDI-MedLine.d44.s2.e0"
            e2="DDI-MedLine.d44.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d44.s3" text="A 1-month washout period was inserted between the treatment periods. "/>
    <sentence id="DDI-MedLine.d44.s4" text="Patients were intravenously injected a chylomicron-like emulsion doubly labeled with 14C-cholesteryl oleate and 3H-triolein at baseline and after treatments. "/>
    <sentence id="DDI-MedLine.d44.s5" text="After etofibrate treatment, there was decrease of total cholesterol and triglyceride plasma levels and a trend to increase high-density lipoprotein cholesterol plasma levels. ">
        <entity id="DDI-MedLine.d44.s5.e0" charOffset="6-15" type="drug" text="etofibrate"/>
    </sentence>
    <sentence id="DDI-MedLine.d44.s6" text="Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment. ">
        <entity id="DDI-MedLine.d44.s6.e0" charOffset="0-9" type="drug" text="Etofibrate"/>
        <entity id="DDI-MedLine.d44.s6.e1" charOffset="44-50"
            type="drug" text="heparin"/>
        <pair id="DDI-MedLine.d44.s6.p0" e1="DDI-MedLine.d44.s6.e0"
            e2="DDI-MedLine.d44.s6.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d44.s7" text="14C-cholesterol ester fractional clearance rate was 260% greater after etofibrate than after placebo. ">
        <entity id="DDI-MedLine.d44.s7.e0" charOffset="71-80"
            type="drug" text="etofibrate"/>
    </sentence>
    <sentence id="DDI-MedLine.d44.s8" text="Therefore, a potent effect of etofibrate on both chylomicron lipolysis and remnant removal was achieved, indicating that this drug can be used to improve this metabolism in future prospective studies.">
        <entity id="DDI-MedLine.d44.s8.e0" charOffset="30-39"
            type="drug" text="etofibrate"/>
    </sentence>
</document>
